Pirtobrutinib Moves to First Line in CLL. Here Is What the Approval Covers.
The FDA has approved the non-covalent BTK inhibitor for adults with previously untreated CLL or SLL without a known 17p deletion. The data come from a trial against chemoimmunotherapy, and the label carries warnings on infections, bleeding and heart rhythm.
Idea in Brief
The Approval
Pirtobrutinib (Jaypirca) is now approved for adults with previously untreated CLL or SLL with no known 17p deletion, adding a first-line indication to its relapsed and refractory uses.
The Evidence
In the phase 3 BRUIN CLL-313 trial of 282 patients, pirtobrutinib reduced the risk of progression compared with bendamustine plus rituximab (HR 0.20) at a median follow-up of 28 months.
The Caveats
The comparator was chemoimmunotherapy, not another targeted therapy, and the label warns of infections, bleeding, cytopenias, arrhythmias, second cancers and liver injury.
Physicians choosing initial therapy for chronic lymphocytic leukemia have a new option. Eli Lilly announced on Oct. 2 that the FDA has approved pirtobrutinib, sold as Jaypirca, for adults with previously untreated CLL or small lymphocytic lymphoma who have no known 17p deletion.
Pirtobrutinib binds BTK non-covalently, and Lilly describes it as the first and only approved drug of that kind. Its earlier U.S. approvals were later in the disease course: relapsed or refractory CLL or SLL after a covalent BTK inhibitor, and relapsed or refractory mantle cell lymphoma after at least two lines of therapy including a BTK inhibitor, the latter under accelerated approval. The new indication moves it to the front of the line for appropriate patients.
What the trial showed
The approval rests on the primary analysis of BRUIN CLL-313, a global, randomized, open-label phase 3 trial that enrolled 282 patients without 17p deletion who had not been treated before. Patients were randomized one to one to pirtobrutinib 200 mg once daily or to bendamustine plus rituximab, according to Lilly's announcement. The results were presented at the American Society of Hematology meeting in December 2025 and published in the Journal of Clinical Oncology.
At a median follow-up of 28 months, progression-free survival assessed by an independent review committee favored pirtobrutinib, with a hazard ratio of 0.20 (95% CI, 0.11 to 0.37). Median progression-free survival had not been reached with pirtobrutinib and was 33.5 months with bendamustine plus rituximab. The overall response rate was 94 percent with pirtobrutinib and 81 percent with chemoimmunotherapy. Complete responses were less frequent with pirtobrutinib, 13 percent versus 21 percent.
The comparator was chemoimmunotherapy. The trial does not tell you how pirtobrutinib performs against other targeted therapies.
That comparator is the first thing a careful reader should note. BRUIN CLL-313 tested pirtobrutinib against chemoimmunotherapy, not against a covalent BTK inhibitor or a venetoclax combination. Lilly's broader program includes BRUIN CLL-314, a head-to-head trial against ibrutinib in BTK inhibitor naive patients, some of them previously untreated, but the first-line approval announced this week is based on CLL-313.
Safety and the label
In CLL-313, adverse reactions led to dose reductions in 3.6 percent of patients on pirtobrutinib and permanent discontinuation in 4.3 percent. Serious adverse reactions occurred in 28 percent, with pneumonia in 5 percent. Lilly said the overall safety profile, including rates of atrial fibrillation or flutter, was consistent with earlier trials.
The prescribing information carries warnings and precautions for infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, hepatotoxicity including drug-induced liver injury, and embryo-fetal toxicity. Across all clinical trials, grade 3 or higher infections occurred in 23 percent of patients and atrial fibrillation or flutter in 3.1 percent. Second primary malignancies developed in 10 percent, most often non-melanoma skin cancer. The label also flags interactions with CYP3A inhibitors and inducers and dose reduction in severe renal impairment.
Clinical Pearls
- The new indication covers adults with previously untreated CLL or SLL who have no known 17p deletion.
- Pirtobrutinib is taken as 200 mg once daily, with or without food, until progression or unacceptable toxicity.
- The label calls for checking bilirubin and transaminases at baseline and throughout treatment, and for withholding the drug if drug-induced liver injury is suspected.
- Avoid strong CYP3A inhibitors and strong or moderate CYP3A inducers; the label gives dose adjustments if a strong inhibitor or a moderate inducer cannot be avoided.
- The label suggests considering withholding the drug 3 to 7 days before and after surgery, depending on the type of surgery and bleeding risk.
- Counsel on sun protection and watch for second primary malignancies, most often non-melanoma skin cancer in trials.
Where it fits
Lilly notes that the National Comprehensive Cancer Network lists pirtobrutinib as a category 2A option for treatment-naive adults with CLL or SLL without del(17p), recommended for older patients with cardiac comorbidities who may need only one lifetime treatment. Jennifer Woyach, MD, a hematologist-oncologist at The Ohio State University Comprehensive Cancer Center, said in Lilly's release that "many people diagnosed with CLL or SLL today may only receive one or two lines of therapy, making initial treatment choices critically important."
For physicians outside hematology, the practical points are narrower. Patients starting first-line BTK inhibition will arrive with new questions about bleeding before procedures, drug interactions, infections, and liver tests. Knowing what the label says on each is part of caring for them, whichever agent their oncologist chooses.
Dr. Okafor is a general internist and contributing editor who writes about primary care redesign and the economics of the exam room.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
